Pharma News
Anticompetitive acquisition forces generics sale
US generics maker CorePharma has had to sell its rights of two generics in order to merge with fellow US drug company Impax Laboratories (Impax). The US Federal Trade Commission (FTC) ruled that Impax’s acquisition of CorePharma would have been anticompetitive unless CorePharma sold its rights and assets for pilocarpine, a drug used to treat dry mouth and glaucoma, and ursodiol, a treatment for liver and gall bladder diseases.
Teva finally makes bid for Mylan
In the wake of many rumours, Israeli generics giant Teva Pharmaceutical Industries (Teva) finally announced on 21 April 2015 that it had made a bid for US-based generics maker Mylan.
Growing investment in Vietnam
Cyprus-based generics company Medochemie is building its second factory in Vietnam. Construction on the site, which will occupy 44,700 square metres, is expected to be completed by the end of 2015 with operations commencing in early 2016.
Teva to buy Auspex Pharma, reinforcing CNS portfolio
Israeli generics giant Teva Pharmaceutical Industries (Teva) announced on 30 March 2015 that it would buy US biopharmaceutical company Auspex Pharmaceuticals (Auspex) for an equity value of US$3.5 billion.
India to set up pharma manufacturing clusters
The Indian Government is planning to set up pharmaceutical manufacturing clusters in order to reduce costs and make the industry more competitive.
Boehringer Ingelheim loses patent battle with India’s Cipla
German pharmaceutical company Boehringer Ingelheim (Boehringer) has lost its patent on the Spiriva respiratory drug in India. The Indian patent office has agreed with the Indian drugmaker Cipla that Boehringer’s Spiriva patent was obvious and was not an invention under India’s patent laws.
Indian Government to launch own brand of generics
Not happy with its current control over the price of drugs in the country, the Indian Government has announced plans to launch its own brand of low cost generics.
Canada clamps down on companies failing to post drug shortage information
The Canadian Government has made it mandatory for drug companies to report actual and anticipated drug shortages. A voluntary system that had been in place was not working well enough, said the country’s Health Minister, Rona Ambrose.
Pfizer sets to lead biosimilars and generics markets
Pharma giant Pfizer has announced it is to buy injectable generics specialist and biosimilars maker Hospira for US$17 billion. The products acquired in the deal will be integrated into Pfizer’s generics unit, Global Established Pharmaceutical (GEP).
Mylan on track to acquire Abbott generics and expand role in women’s health
The European Commission (EC) has approved Mylan’s acquisition of Abbott Laboratories' Non-US Developed Markets Specialty and Branded Generics Business (Abbott EPD-DM), subject to conditions. US-based generics manufacturer Mylan will have to sell off a number of its businesses in France, Germany, Ireland, Italy and UK in order to satisfy European Union merger regulations.
